IMV INC.

IMV
Delayed Quote. Delayed  - 01/26 11:06:34 am
4.34CAD -4.62%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - Other
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.
Sales per Business
20182019
CAD
(in Million)
%CAD
(in Million)
%
Immunotherapies 0.082100% 0.059100%
Sales per region
20182019
CAD
(in Million)
%CAD
(in Million)
%
Canada 0.082100% 0.059100%
Managers
Name Title
Frederic Ors Chief Executive Officer & Non-Independent Director
Andrew J. Sheldon Chairman
Ryan Marshall Vice President-Project Management & Operations
Pierre Labbé Chief Financial Officer
Marianne Stanford Vice President-Research & Development
Joanne Schindler Chief Medical Officer
James Willis Hall Independent Director
Wayne F. Pisano Independent Director
Shermaine Tilley Independent Director
Julia Paige Gregory Independent Director
Shareholders
Name Equities %
Ruffer LLP 7,453,399 11.1%
Fonds de Solidarité FTQ 5,111,533 7.62%
VHCP Management LLC 3,150,000 4.69%
Albert Scardino 2,362,974 3.52%
Fidelity (Canada) Asset Management ULC 800,000 1.19%
Fidelity Investments Canada ULC 710,000 1.06%
Wells Fargo Clearing Services LLC 355,038 0.53%
Ghost Tree Capital LLC 325,000 0.48%
Frederic Ors 284,907 0.42%
Intact Investment Management, Inc. 242,418 0.36%
Company contact information
IMV, Inc.
130 Eileen Stubbs Avenue
Suite 19
Dartmouth, NS B3B 2C4

Phone : +1.902.492.1819
Fax : +1.902.492.0888
Web : http://www.imv-inc.com
Sector Biotechnology & Medical Research - Other
1st jan.Capi. (M$)
IMV INC.16.97%247
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.2.15%35 090
SEAGEN INC.2.84%32 583
HANGZHOU TIGERMED CONSULTING CO.,LTD18.50%25 245
INCYTE CORPORATION12.54%22 009
ALNYLAM PHARMACEUTICALS, INC.35.18%20 412
PHARMARON BEIJING CO., LTD.40.91%20 367
BIO-TECHNE CORPORATION10.99%13 607
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.12.13%13 607
CRISPR THERAPEUTICS AG18.37%13 396
QIAGEN N.V.1.89%12 246
PPD, INC.1.99%12 203
ICON PUBLIC LIMITED COMPANY10.07%11 326
IONIS PHARMACEUTICALS, INC.12.81%8 918
ACADIA PHARMACEUTICALS INC.0.92%8 577
PRA HEALTH SCIENCES, INC.4.74%8 428
SYNEOS HEALTH, INC.14.27%8 090
UNITED THERAPEUTICS CORPORATION11.57%7 526